Market Overview - The Shanghai Composite Index fell by 0.44% to close at 3384.82 points, with a high of 3406.45 points [1] - The Shenzhen Component Index decreased by 0.86% to 10162.18 points, reaching a peak of 10256.85 points [1] - The ChiNext Index dropped by 1.17% to 2037.27 points, with a maximum of 2063.87 points [1] ETF Market Performance - The median return of stock ETFs was -0.67% [2] - The highest performing scale index ETF was Penghua CSI 800 Free Cash Flow ETF with a return of 0.39% [2] - The highest performing industry index ETF was China Merchants CSI Hong Kong-Shanghai 500 Pharmaceutical Health ETF with a return of 1.05% [2] - The highest performing strategy index ETF was China Fortune CSI All Share Free Cash Flow ETF with a return of 0.68% [2] - The highest performing style index ETF was China Merchants CSI Bank AH Price Preferred ETF with a return of 0.59% [2] - The highest performing theme index ETF was China Tai Bai Rui CSI Hong Kong-Shanghai Innovative Drug Industry ETF with a return of 1.61% [2] ETF Performance Rankings - The top three ETFs by return were: - Huatai-PB CSI Hong Kong-Shanghai Innovative Drug Industry ETF (1.61%) - Tibet Dongcai CSI Hong Kong-Shanghai Innovative Drug Industry ETF (1.41%) - GF Guozheng Grain Industry ETF (1.3%) [5] - The bottom three ETFs by return were: - Huatai-PB CSI Information Technology Application Innovation Industry ETF (-3.76%) - Huabao CSI Information Technology Application Innovation Industry ETF (-3.68%) - Huaxia CSI Information Technology Application Innovation Industry ETF (-3.21%) [6] ETF Fund Flows - The top three ETFs by fund inflow were: - Huaxia Shanghai Stock Exchange Sci-Tech Innovation Board 50 ETF (inflow of 645 million) - Fortune CSI Military Industry Leaders ETF (inflow of 309 million) - Guolian An CSI All Share Semiconductor Products and Equipment ETF (inflow of 255 million) [8] - The top three ETFs by fund outflow were: - Huatai-PB CSI 300 ETF (outflow of 1.1 billion) - Guotai Guozheng Information Technology Innovation Theme ETF (outflow of 704 million) - Huaxia CSI Information Technology Application Innovation Industry ETF (outflow of 644 million) [9] ETF Margin Trading Overview - The top three ETFs by margin buying were: - Huaxia Shanghai Stock Exchange Sci-Tech Innovation Board 50 ETF (buying amount of 648 million) - Guotai CSI All Share Securities Company ETF (buying amount of 224 million) - Huatai-PB CSI 300 ETF (buying amount of 210 million) [11] - The top three ETFs by margin selling were: - Huatai-PB CSI 300 ETF (selling amount of 20.71 million) - Huaxia CSI 1000 ETF (selling amount of 17.64 million) - Southern CSI 1000 ETF (selling amount of 13.50 million) [12] Institutional Insights - The innovation drug sector is expected to maintain its growth, driven by "innovation + internationalization" trends, with policy support and increasing global competitiveness [13] - The domestic market is anticipated to recover by 2025, with potential improvements in the medical service sector and AI healthcare innovations [13] - The pharmaceutical sector has shown strong performance recently, influenced by significant collaborations, and is recommended for increased allocation [14]

Group 1 - The core viewpoint of the article highlights the performance of the CSI Hong Kong-Shanghai Innovative Drug Industry Index, which rose by 2.51% to 1955.39 points, with a trading volume of 33.441 billion yuan [1] - The index has shown significant growth, increasing by 6.55% over the past month, 12.29% over the past three months, and 22.60% year-to-date [1] - The index is composed of up to 50 representative securities from the mainland and Hong Kong markets, focusing on companies involved in innovative drug research and production, reflecting the overall performance of the innovative drug industry [1] Group 2 - The index is adjusted semi-annually, with changes implemented on the next trading day following the second Friday of June and December each year [1] - Weight factors are generally fixed until the next scheduled adjustment, with special circumstances allowing for temporary adjustments [1] - The index will be modified if a sample company is delisted or if there are significant corporate changes such as mergers or acquisitions [1] Group 3 - Public funds tracking the SHS Innovative Drug Index include various ETFs and fund products from companies like Guotai, Xizang Dongcai, and Huatai Bairui [2]